Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

H. Taha, A. Das, S. Das

    Research output: Contribution to journalArticle

    14 Citations (Scopus)
    13 Downloads (Pure)

    Abstract

    Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI), which has now been licensed to be used in different countries including the UK. Earlier studies have demonstrated that DTG when used with nucleoside backbone in treatment-naïve and -experienced patients has been well tolerated and demonstrated virological suppression comparable to other INSTIs and superiority against other first-line agents, including efavirenz and boosted protease inhibitors. Like other INSTIs, DTG uses separate metabolic pathways compared to other antiretrovirals and is a minor substrate for CYP-450. It does not appear to have a significant interaction with drugs, which uses the CYP-450 system. Nonetheless, it uses renal solute transporters that may potentially inhibit the transport of other drugs and can have an effect on the elimination of other drugs. However, the impact of this mechanism appears to be very minimal and insignificant clinically. The side effect profiles of DTG are similar to raltegravir and have been found to be well tolerated. DTG has a long plasma half-life and is suitable for once daily use without the need for a boosting agent. DTG has all the potential to be used as a first-line drug in combination with other nucleoside backbones, especially in the form of a single tablet in combination with abacavir and lamivudine. The purpose of this review article is to present the summary of the available key information about the clinical usefulness of DTG in the treatment of HIV infection
    Original languageEnglish
    Pages (from-to)339-352
    JournalInfection and Drug Resistance
    Volume8
    DOIs
    Publication statusPublished - Oct 2015

    Fingerprint

    Acquired Immunodeficiency Syndrome
    HIV
    efavirenz
    Nucleosides
    Therapeutics
    Integrases
    Drug Combinations
    Metabolic Networks and Pathways
    dolutegravir
    Protease Inhibitors
    Drug Interactions
    Pharmaceutical Preparations
    Tablets
    HIV Infections
    Half-Life
    Kidney

    Bibliographical note

    This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

    Keywords

    • dolutegravir
    • integrase inhibitors
    • HIV
    • antiretroviral
    • treatment

    Cite this

    Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. / Taha, H.; Das, A.; Das, S.

    In: Infection and Drug Resistance, Vol. 8, 10.2015, p. 339-352.

    Research output: Contribution to journalArticle

    Taha, H. ; Das, A. ; Das, S. / Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. In: Infection and Drug Resistance. 2015 ; Vol. 8. pp. 339-352.
    @article{063f8e2f336047359893cf4c74a8af64,
    title = "Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS",
    abstract = "Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI), which has now been licensed to be used in different countries including the UK. Earlier studies have demonstrated that DTG when used with nucleoside backbone in treatment-na{\"i}ve and -experienced patients has been well tolerated and demonstrated virological suppression comparable to other INSTIs and superiority against other first-line agents, including efavirenz and boosted protease inhibitors. Like other INSTIs, DTG uses separate metabolic pathways compared to other antiretrovirals and is a minor substrate for CYP-450. It does not appear to have a significant interaction with drugs, which uses the CYP-450 system. Nonetheless, it uses renal solute transporters that may potentially inhibit the transport of other drugs and can have an effect on the elimination of other drugs. However, the impact of this mechanism appears to be very minimal and insignificant clinically. The side effect profiles of DTG are similar to raltegravir and have been found to be well tolerated. DTG has a long plasma half-life and is suitable for once daily use without the need for a boosting agent. DTG has all the potential to be used as a first-line drug in combination with other nucleoside backbones, especially in the form of a single tablet in combination with abacavir and lamivudine. The purpose of this review article is to present the summary of the available key information about the clinical usefulness of DTG in the treatment of HIV infection",
    keywords = "dolutegravir, integrase inhibitors, HIV, antiretroviral, treatment",
    author = "H. Taha and A. Das and S. Das",
    note = "This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php",
    year = "2015",
    month = "10",
    doi = "10.2147/IDR.S68396",
    language = "English",
    volume = "8",
    pages = "339--352",
    journal = "Infection and Drug Resistance",
    issn = "1178-6973",
    publisher = "Dove Medical Press",

    }

    TY - JOUR

    T1 - Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

    AU - Taha, H.

    AU - Das, A.

    AU - Das, S.

    N1 - This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

    PY - 2015/10

    Y1 - 2015/10

    N2 - Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI), which has now been licensed to be used in different countries including the UK. Earlier studies have demonstrated that DTG when used with nucleoside backbone in treatment-naïve and -experienced patients has been well tolerated and demonstrated virological suppression comparable to other INSTIs and superiority against other first-line agents, including efavirenz and boosted protease inhibitors. Like other INSTIs, DTG uses separate metabolic pathways compared to other antiretrovirals and is a minor substrate for CYP-450. It does not appear to have a significant interaction with drugs, which uses the CYP-450 system. Nonetheless, it uses renal solute transporters that may potentially inhibit the transport of other drugs and can have an effect on the elimination of other drugs. However, the impact of this mechanism appears to be very minimal and insignificant clinically. The side effect profiles of DTG are similar to raltegravir and have been found to be well tolerated. DTG has a long plasma half-life and is suitable for once daily use without the need for a boosting agent. DTG has all the potential to be used as a first-line drug in combination with other nucleoside backbones, especially in the form of a single tablet in combination with abacavir and lamivudine. The purpose of this review article is to present the summary of the available key information about the clinical usefulness of DTG in the treatment of HIV infection

    AB - Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI), which has now been licensed to be used in different countries including the UK. Earlier studies have demonstrated that DTG when used with nucleoside backbone in treatment-naïve and -experienced patients has been well tolerated and demonstrated virological suppression comparable to other INSTIs and superiority against other first-line agents, including efavirenz and boosted protease inhibitors. Like other INSTIs, DTG uses separate metabolic pathways compared to other antiretrovirals and is a minor substrate for CYP-450. It does not appear to have a significant interaction with drugs, which uses the CYP-450 system. Nonetheless, it uses renal solute transporters that may potentially inhibit the transport of other drugs and can have an effect on the elimination of other drugs. However, the impact of this mechanism appears to be very minimal and insignificant clinically. The side effect profiles of DTG are similar to raltegravir and have been found to be well tolerated. DTG has a long plasma half-life and is suitable for once daily use without the need for a boosting agent. DTG has all the potential to be used as a first-line drug in combination with other nucleoside backbones, especially in the form of a single tablet in combination with abacavir and lamivudine. The purpose of this review article is to present the summary of the available key information about the clinical usefulness of DTG in the treatment of HIV infection

    KW - dolutegravir

    KW - integrase inhibitors

    KW - HIV

    KW - antiretroviral

    KW - treatment

    U2 - 10.2147/IDR.S68396

    DO - 10.2147/IDR.S68396

    M3 - Article

    VL - 8

    SP - 339

    EP - 352

    JO - Infection and Drug Resistance

    JF - Infection and Drug Resistance

    SN - 1178-6973

    ER -